Core Points - Zhejiang Shouxiangu Pharmaceutical Co., Ltd. will hold a Q3 2025 performance briefing on November 18, 2025, to discuss its operational results and financial status [2][4] - The meeting will be conducted via video recording combined with online interaction, allowing investors to submit questions in advance [3][7] - Key executives, including the Chairman and General Manager, will participate in the briefing [5] Meeting Details - The performance briefing is scheduled for November 18, 2025, from 13:00 to 14:30 [4] - It will take place at the Shanghai Stock Exchange Roadshow Center [4] - Investors can participate online and submit questions from November 11 to November 17, 2025 [7][8] Bond Interest Payment Announcement - The company announced that the "Shou 22 Convertible Bond" will start paying interest on November 17, 2025, for the period from November 17, 2024, to November 16, 2025 [11][17] - The interest rate for this period is set at 1%, meaning each bond with a face value of 100 RMB will yield 1.00 RMB in interest [17][23] - The bond's interest payment registration date is November 14, 2025, with the ex-dividend date also on November 17, 2025 [18][19] Bond Issuance Overview - The "Shou 22 Convertible Bond" was issued with a total scale of 398 million RMB and has a maturity of six years [12] - The bond's initial conversion price is 38.08 RMB per share, with the latest conversion price at 36.84 RMB per share [12][13] - The bond has a credit rating of "AA-" with a stable outlook [14][15]

Core Viewpoint - The company has decided not to adjust the conversion price of the "Shou 22 Convertible Bonds" despite triggering conditions for a downward adjustment, citing confidence in its future development potential and the need to treat all investors fairly [1][6]. Group 1: Convertible Bond Issuance and Terms - The company issued 3.98 million convertible bonds on November 17, 2022, with a total amount of 398 million yuan, and the bonds are set to mature on November 16, 2028 [2]. - The initial conversion price was set at 38.08 yuan per share, which has been adjusted to 36.84 yuan per share as of the latest update [2][4]. - The conversion period for the bonds is from May 23, 2023, to November 16, 2028 [1]. Group 2: Conversion Price Adjustment Conditions - The conversion price can be adjusted downward if the company's stock price is below 85% of the current conversion price for at least 15 out of 30 consecutive trading days [5]. - The specific threshold for triggering the adjustment was set at 31.31 yuan per share [4][5]. Group 3: Board Decision on Price Adjustment - On September 15, 2025, the board unanimously decided not to adjust the conversion price, with all five votes in favor and no opposition [5]. - The board will reassess the situation if the adjustment conditions are triggered again within the next six months, starting from September 16, 2025 [6].

Core Viewpoint - Zhejiang Shouxiangu Pharmaceutical Co., Ltd. has decided not to adjust the conversion price of its "Shou 22 Convertible Bonds" despite triggering the downward adjustment clause due to stock price performance [2][7]. Group 1: Convertible Bond Details - The "Shou 22 Convertible Bonds" were issued on November 17, 2022, with a total amount of 398 million yuan and a maturity period of six years [3]. - The initial conversion price was set at 38.08 yuan per share, which has been adjusted to 36.84 yuan per share as of May 23, 2023 [5][6]. - The bond's conversion period is from May 23, 2023, to November 16, 2028 [5]. Group 2: Price Adjustment Clause - The downward adjustment clause is triggered when the stock price closes below 85% of the current conversion price for at least 15 out of 30 consecutive trading days [6]. - From August 26 to September 15, 2025, the stock price met the criteria for triggering this clause [2][6]. Group 3: Board Decision - The board of directors held a meeting on September 15, 2025, and unanimously decided not to adjust the conversion price, with all five votes in favor [7]. - The decision was made considering the company's future potential and market conditions, aiming to protect the interests of all investors [7].

Group 1 - The company announced that it will not adjust the conversion price of the "Shou 22 Convertible Bond" downward during the next six months, from September 16, 2025, to March 15, 2026 [1] - If the downward adjustment clause is triggered again, the board will hold another meeting to decide whether to exercise the right to adjust the conversion price [1] - The first trading day for recalculating the conversion price will be March 16, 2026, or the next trading day if it falls on a non-trading day [1]

Meeting Overview - The second meeting of the fifth board of directors of Zhejiang Shouxiangu Pharmaceutical Co., Ltd. was held on August 27, 2025, in accordance with the Company Law and the Articles of Association [1] Financial Reporting - The board approved the 2025 semi-annual report, which complies with the relevant regulations and is accurate and complete [2] - The voting results for the semi-annual report were unanimous with 9 votes in favor, 0 against, and 0 abstentions [2] Fund Management - The board approved the special report on the storage and actual use of raised funds for the first half of 2025, confirming compliance with regulations and accurate disclosure [2] - The voting results for the fund management report were also unanimous with 9 votes in favor, 0 against, and 0 abstentions [2] Related Party Transactions - The board approved the proposal to increase the estimated amount of daily related party transactions for 2025, specifically raising the deposit limit with Wuyi Rural Commercial Bank to 550 million yuan [3][4] - The voting results for this proposal were 6 votes in favor, 0 against, and 0 abstentions, with certain directors abstaining from voting [3] Corporate Governance Changes - The board approved a proposal to change the company's registered capital and abolish the supervisory board, transferring its responsibilities to the audit committee [4] - The registered capital was adjusted from 198,241,889 yuan to 198,243,911 yuan due to the conversion of bonds [4] - The proposal to amend the Articles of Association was also approved with unanimous support [4] Upcoming Shareholder Meeting - The company plans to hold its first extraordinary general meeting of 2025 on September 18, 2025, in accordance with the Company Law and Articles of Association [5] - The voting results for the meeting proposal were unanimous with 9 votes in favor, 0 against, and 0 abstentions [5]

Meeting Overview - The second meeting of the fifth Supervisory Board of Zhejiang Shuxian Valley Pharmaceutical Co., Ltd. was held on August 27, 2025, with all three supervisors present [1] - The meeting was chaired by Ms. Xu Lingyan and complied with relevant regulations [1] Financial Report Approval - The Supervisory Board approved the 2025 semi-annual report, which accurately reflects the company's financial status and operational results, adhering to regulatory requirements [2] - The report was deemed to have no insider information leakage or other actions harming the company's interests [2] Fund Usage Report Approval - The Supervisory Board approved the special report on the storage and actual use of raised funds for the first half of 2025, confirming compliance with relevant regulations [2] - The report accurately reflects the usage of raised funds and fulfills information disclosure obligations [2] Related Party Transactions - The Supervisory Board approved the proposal to increase the estimated amount of daily related party transactions for 2025, stating that these transactions are based on operational needs and do not harm the interests of the company or shareholders [3] - The pricing of transactions with related parties is not substantially different from that with non-related parties [3] Capital Change and Governance Structure - The Supervisory Board approved a proposal to change the company's registered capital and abolish the Supervisory Board, transferring its responsibilities to the Audit Committee of the Board [4] - The registered capital will change from 198,241,889.00 yuan to 198,243,911.00 yuan due to the conversion of bonds into shares [4] - The proposal requires approval at the company's first extraordinary general meeting of 2025 [4]

Core Viewpoint - The announcement details the conversion results and share changes related to the "Shou 22 Convertible Bonds" issued by Zhejiang Shouxiangu Pharmaceutical Co., Ltd, highlighting the bond's issuance, conversion period, and adjustments to the conversion price due to equity distributions [1][2][3]. Group 1: Bond Issuance and Trading - The company issued 3.98 million convertible bonds with a face value of 100 yuan each, totaling 398 million yuan, approved by the China Securities Regulatory Commission [1]. - The bonds began trading on the Shanghai Stock Exchange on December 12, 2022, under the name "Shou 22 Convertible Bonds" with the code "113660" [1]. Group 2: Conversion Period and Price Adjustments - The conversion period for the bonds is from May 23, 2023, to November 16, 2028, with the initial conversion price set at 38.08 yuan per share [1]. - The conversion price was adjusted to 37.65 yuan per share on July 4, 2023, and will further adjust to 37.27 yuan on June 20, 2024, and to 36.84 yuan on June 6, 2025, due to equity distributions [1][2]. Group 3: Conversion Status - As of June 30, 2025, the total amount converted from the "Shou 22 Convertible Bonds" is 311,000 yuan, representing 0.0781% of the total issuance, resulting in 8,150 shares, which is 0.0041% of the company's total shares before conversion [2][3]. - The amount of unconverted bonds as of June 30, 2025, is 397.689 million yuan, accounting for 99.92% of the total issuance [3][4]. Group 4: Share Capital Changes - The total share capital before the conversion was 198,243,858 shares, which increased to 198,243,911 shares after the conversion of 53 shares [4].

Core Viewpoint - Zhejiang Shouxiangu Pharmaceutical Co., Ltd. maintains its credit rating of "AA-" for both its corporate and convertible bonds, with a stable outlook as per the latest tracking report by Zhongzheng Pengyuan [1][2]. Group 1: Credit Rating Details - The previous credit rating for the company and its convertible bonds was "AA-", with a stable outlook, issued on June 25, 2024 [1][2]. - The latest tracking credit rating report was issued on June 20, 2025, confirming the ratings remain unchanged [2]. Group 2: Regulatory Compliance - The company conducted the credit rating in accordance with the "Measures for the Issuance and Trading of Corporate Bonds" and the "Listing Rules for Corporate Bonds on the Shanghai Stock Exchange" [1].

Core Points - Zhejiang Shuxian Valley Pharmaceutical Co., Ltd. announced a cash dividend of 0.27 yuan per share for the fiscal year 2024, approved at the annual shareholders' meeting on May 13, 2025 [2][3][4] - The total cash dividend distribution amounts to approximately 53.53 million yuan, based on a total share capital of 198,243,911 shares [4] - The dividend will be distributed to all shareholders registered with the China Securities Depository and Clearing Corporation Limited Shanghai Branch as of the close of trading on the record date [3][4] Distribution Plan - The cash dividend distribution is based on the company's total share capital as of the record date, with each share receiving a cash dividend of 0.27 yuan (before tax) [4] - The distribution will be managed by the China Securities Depository and Clearing Corporation, with shareholders who have completed designated transactions able to receive their dividends on the payment date [6][8] Taxation Details - For individual shareholders holding unrestricted shares, no income tax will be withheld at the time of dividend distribution; tax will be calculated based on the holding period when shares are sold [9] - For shares held for less than one month, the tax rate is 20%; for one month to one year, the tax rate is 10%; and for over one year, dividends are exempt from personal income tax [9] - For foreign institutional investors, a 10% withholding tax will apply, resulting in a net dividend of 0.243 yuan per share [10] Convertible Bond Adjustment - The company announced an adjustment to the conversion price of its convertible bonds ("Shu 22 Convertible Bonds") due to the dividend distribution, changing from 37.11 yuan to 36.84 yuan per share [19][21] - The adjustment will take effect on June 6, 2025, with the bonds being suspended from conversion from May 28 to June 5, 2025 [21]

Group 1 - The company will suspend the conversion of its convertible bonds "寿 22 转债" from May 28, 2025, until the equity distribution registration date due to the implementation of the 2024 profit distribution plan [1][2] - The profit distribution plan proposes a cash dividend of 2.70 yuan (including tax) for every 10 shares based on the total share capital on the equity distribution registration date [1][2] - The company will announce the implementation of the equity distribution and the adjustment of the conversion price for "寿 22 转债" on May 29, 2025 [2] Group 2 - Holders of "寿 22 转债" can convert their bonds until May 27, 2025, to enjoy the equity distribution benefits [2] - The company will adjust the conversion price of "寿 22 转债" in accordance with the terms outlined in the bond issuance prospectus after the equity distribution [2] - The company has provided contact information for inquiries regarding the announcement [2]